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Abstract:  Three new minor components, the pyridoacridine alkaloids 1-hydroxy-
deoxyamphimedine (1), 3-hydroxy-deoxyamphimedine (2), debromopetrosamine (3), and 
three known compounds, amphimedine (4), neoamphimedine (5) and deoxyamphimedine 
(6), have been isolated from the sponge Xestospongia cf. carbonaria, collected in Palau. 
Structures were assigned on the basis of extensive 1D and 2D NMR studies as well as 
analysis by HRESIMS. Compounds 1–6 were evaluated in a zebrafish phenotype-based 
assay. Amphimedine (4) was the only compound that caused a phenotype in zebrafish 
embryos at 30 µM. No phenotype other than death was observed for compounds 1–3, 5, 6. 
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1. Introduction 
Zebrafish have been identified as a valuable whole animal platform for phenotypic screening at 
various stages of the drug discovery process [1–4]. Some of the advantages that zebrafish offer in 
laboratory assays include the transparency of their embryos, allowing direct observation of organ 
morphology during treatment or visualization of specific molecular species using hybridization 
techniques; rapid development and short reproductive cycles; and easy maintenance in 96-well plates. 
Although the potential value of zebrafish in screening natural product extract libraries has been noted 
[5,6], to date relatively few zebrafish-based natural product screening programs, from either plants or 
marine sources, have been reported [7–9]. As part of a pilot study, we screened a prefractionated 
extract library [10] from marine invertebrates for zebrafish phenotypic activity. This small library 
included four fractions from each of forty organisms  that were selected based on a known high 
incidence of cytotoxic compounds in their extracts. The rationale behind organism selection was to 
determine if our fractionation method is effective at enabling observation of phenotypic activity in the 
presence of strong background cytotoxicity. Within the 160 fractions, 25% exhibited embryo toxicity 
whereas an additional 8% caused various other phenotypic responses 24 hours after treatment. We 
report here the results from one of the organisms displaying activity, the sponge Xestospongia cf. 
carbonaria collected in Palau, which caused a phenotype of abnormal notochord development and 
death in the primary screen. Three new pyridoacridine alkaloids 1–3 as well as the known compounds 
4–6, were isolated from a large scale extraction of this sponge. The pure compounds 1–6  were 
evaluated in the zebrafish assay, identifying amphimedine (4) as the agent responsible for the 
phenotypic response in the primary screen. 
2. Results and Discussion 
The specimen of Xestospongia cf. carbonaria was extracted with MeOH. The crude extract was 
separated on HP20SS resin according to a prefractionation protocol previously reported by this lab 
[11]. Subsequent bioassay-guided fractionation resulted in the isolation of the pyridoacridine alkaloids 
1–3  as their respective trifluoroacetate salts, along with the known compounds amphimedine (4), 
neoamphimedine (5), and deoxyamphimedine (6). 1-Hydroxy-deoxyamphimedine (1) was obtained as 
a red-orange amorphous solid. A molecular ion in the positive HRESIMS spectrum at m/z 314.0945 
corresponded to a molecular formula of C19H12N3O2  (∆  4.8 ppm), which was isomeric with 
amphimedine (4) and neoamphimedine (5). The strong absorption bands at 3382 and 1687 cm
-1 in the 
IR spectrum indicated that 1  contained a hydroxyl group and a conjugated carbonyl group. The 
structure of 1 was elucidated by interpretation of NMR data (Table 1) and comparison with spectral 
data for deoxyamphimedine (6). The only difference observed in the NMR data between 1 and 6 was 
in the A ring system. For 1, two doublets and one doublet of doublets at δH 7.48 (J = 8.0 Hz), 
8.45 (J = 8.0 Hz) and 7.91 (J = 8.0, 8.0 Hz) ppm, respectively, indicated an additional hydroxyl present 
at either C-1 or C-4. The position of the hydroxyl group was identified as C-1 based on a NOESY 
correlation between signals at δH  8.45 (H-4) and 9.13 (H-5) ppm. The gHMBC spectrum also 
supported the assignment of 1 as 1-hydroxy-deoxyamphimedine. 
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Table 1. 
1H and 
13C-NMR data of pyridoacridine alkaloids (1–3). 
Posn.  1  2  3 
  δH, mult (JH-H)  δC, mult 
a  δH, mult (JH-H)  δC, mult 
b  δH, mult (JH-H)  δC, mult 
c 
1    156.1  C  8.39, d (9.0)  135.8  CH  8.19, d (9.0)  143.0  CH 
2  7.48, d (8.0)  116.5  CH  7.63, dd (9.0, 2.5)  124.3  CH  7.73, dd (9.0, 7.5)  128.4  CH 
3  7.91, dd (8.0, 8.0)   133.3  CH    162.7  C  7.84, dd (8.0, 7.5)  133.5  CH 
4  8.45, d (8.0)  114.5  CH  8.20, d (2.5)  108.0  CH  9.27, d (8.0)  125.1  CH 
4a    123.8  C    126.6  C    125.2  C 
4b    137.9  C    140.9  C    115.8  C 
5  9.13, d (6.0)  121.8  CH  9.00, d (6.0)  122.9  CH    187.2  C 
6  9.37, d (6.0)  150.2  CH  9.30, d (6.0)  151.4  CH  4.41, s   71.4  CH2 
7a    147.0  C    149.5  C    115.1  C 
8    180.0  C    180.6  C    161.0  C 
8a    130.3  C    130.8  C    132.7  C 
9  9.87, s  146.0  CH  9.82, s  147.9  CH  9.72, s  145.9  CH 
11  9.40, d (6.5)  147.8  CH  9.17, d (6.5)  148.7  CH  8.75, d (6.5)  142.0  CH 
12  9.90, d (6.5)  123.5  CH  9.38, d (6.5)  124.1  CH  9.39, d (6.5)  122.9  CH 
12a    147.9  C    149.2  C    143.5  C 
12b    143.1  C    145.5  C    139.5  C 
12c    120.1  C    120.8  C    129.9  C 
13a    134.4  C    141.5  C    143.1  C 
14  4.57, s  48.3  CH3  4.58, s  49.3  CH3  4.53  49.0  CH3 
15              3.84, s (3H)  54.1  CH3 
16              3.84, s (3H)  54.1  CH3 
a. 13C NMR data assigned based on the HSQC and HMBC in DMSO-d6 (500 MHz). 
b. 13C NMR data assigned based on 
the HSQC and HMBC in CD3OD (600 MHz). 
c. 
13C NMR data assigned based on the HSQC and HMBC in CD3CN  
(500 MHz). 
A molecular formula of C19H12N3O2 for 3-hydroxy-deoxyamphimedine (2) was consistent with both 
the HRESIMS (m/z 314.0938, [M]
+, ∆ 2.5 ppm) and with proton and carbon counts in the respective 
NMR spectra. Compound 2 is isomeric with 1 and showed a very similar IR spectrum suggesting the 
presence of a hydroxyl group (νmax 3421 cm
-1) and an iminoquinone (νmax 1685 cm
-1). 
1H chemical 
shifts and coupling patterns for the A ring were different from those of 1. The 
1H NMR spectrum 
of 2 contained a broad doublet at δH 8.20 ppm (H-4, J = 2.5 Hz) and a doublet of doublets at δH 
7.63 ppm (H-2, J = 9.0, 2.5 Hz) indicating that the hydroxyl was at C-3. Thus, the A ring in 2 was 
identified as being a 1, 3, 4-trisubstituted benzene, which marks the difference between 1 and 2. A 1D 
NOESY experiment also showed a correlation between signals at δH  8.20 (H-4) and   
9.00 ppm (H-5) in 2, thus confirming the identity of 2 as 3-hydroxy-deoxyamphimedine. 
The structure of debromopetrosamine (3) appeared in a review on marine pyridoacridine alkaloids 
[12], but the compound has never been formally described. The alkaloid 3 was isolated as a purple-blue 
amorphous solid and determined to have a molecular formula of C21H18N3O2 by HRESIMS (m/z 
344.1415, [M]
+, ∆ 4.6 ppm). A strong and broad absorption band at 1682 cm
-1 in the IR spectrum 
suggested that 3 contained multiple conjugated ketones. The gHSQC spectrum and 
1H NMR data Mar. Drugs 2010, 8       
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indicated seven aromatic protons, two methylene protons (δH 4.41, H-6) and nine N-methyl protons  
(δH 4.53, Me-14 and δH 3.84, Me-15, 16). The 
1H chemical shifts and coupling patterns of ring A in 3 
were nearly identical with those of amphimedine (4) and neoamphimedine (5). Ortho-coupled proton 
resonances at δH 8.75 (H-11) and δH 9.39 (H-12), along with a low-field proton at δH 9.72 (H-9) 
indicated  3 contained the same E ring pattern as deoxyamphimedine (6) although the 
1H and 
13C 
chemical shifts of Me-14  showed it was not attached to a quaternary nitrogen. The degenerate   
N,N-dimethyl proton singlets at δH 3.84 showed gHMBC correlations to an N-methyl carbon at δC 54.1, 
an aromatic quaternary carbon at δC 115.1 (C-7a), the methylene carbon at δC 71.4 (C-6) and a weak 
long- range correlation to δC 187.2 (C-5). Additionally, the gHMBC spectrum showed correlations 
from methylene protons δH 4.41 (H-6) to the degenerate N-methyl carbons C-15 and C-16 (δC 
54.1), a quaternary aromatic carbon at δC 115.8 (C-4b), as well as the carbonyl at δC 187.2 (C-5). The 
gHMBC correlations between H-4 and C-4b; H-9 and C-8; H-11 and C12a; and H12 to C12b and C-8a 
elucidated the connectivities of the A, B, C, and D rings. COSY correlations from δH 9.72 (H-9) to 
δH 8.75 (H-11); from δH 9.27 (H-4) to δH 7.84 (H-3); from δH 8.19 (H-1) to δH 7.84 (H-3) and δH 
7.73 (H-2); from δH 4.41 (H-6) to δH 3.84 (H-15, H-16); and from δH 8.75 (H-11) to δH 9.39 (H-12) and 
δH 4.53 (H-14) further confirmed the carbon connections. Based on these assignments and comparison 
of spectral data with those from the known compounds petrosamine [13] and petrosamine B [14], we 
conclude that 3 is debromopetrosamine. 
Figure 1. Structures of compounds 1–6. 
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Of the pure compounds (1–6) isolated from this sponge, only amphimedine (4) showed a phenotype 
in the zebrafish assay at 30 µM. Embryos exposed to amphimedine (4) exhibited necrosis, pericardial 
edema and an enlarged yolk with thin extension (Figure 2B, D). The embryos also appeared short and Mar. Drugs 2010, 8       
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grainy, with an extended heart, weak heartbeat, no circulation, and irregular curvature of the tail 
(Figure 2B, D). In order to further characterize the phenotypes induced by amphimedine (4), a series of 
in situ hybridization experiments were carried out that utilized digoxigenin-labeled antisense RNA 
probes against various regulatory genes involved in development and differentiation. These studies 
enabled selective high-contrast imaging of various organs. Treated embryos showed wavy notochord, 
spinal cord and abnormally shaped somites after imaging of  ntl,  hnf6  and  myoD, respectively   
(Figure 3B, D, F). They also lack pectoral fin buds, have slightly smaller eyes and shortened brain 
regions as shown  by the imaging  of known brain markers such as dlx2,  otx2,  fgf8  and  zash1a  
(Figure 3H, J, L, N, P, R). The variety and severity of phenotypic responses induced by amphimedine 
(4) suggest interference with a fundamental process  in embryonic development or action against 
multiple systems. Unfortunately, at this time it is not possible to infer from the pattern of activities 
observed which specific targets amphimedine (4) might be modulating. 
Figure 2.  Amphimedine-treated embryos exhibit heart, yolk and body shape defects. 
Treatment of embryos seven hours post-fertilization (hpf) with 30 μM amphimedine (amp) 
resulted in pericardial edema (arrow), extended heart (arrow head), enlarged yolk with thin 
extension (*), curving of the body and general necrosis at 24 hours post-treatment (hpt; B) 
and 48 hpt (D) compared to the DMSO-treated controls (A and C, respectively). 
 
Since the first pyridoacridine, amphimedine (4) was identified in 1983 [15], over a  hundred 
pyridoacridine alkaloids have been isolated from marine sources [16]. The bioactivity most often 
reported for pyridoacridine molecules has been cytotoxicity [17–22], although a wide array of other 
biological activities have also been documented, such as antimicrobial [23,24], anti-viral [25], and 
DNA-directed activities [26]. Neoamphimedine (5), a known topoisomerase II inhibitor [17], was not 
active in the zebrafish screen, which is consistent with our observations that other known top2 
inhibitors, including etoposide, daunorubicin and doxorubicin show no phenotype, illustrating both the 
selectivity of the assay and the remarkable versatility of the pyridoacridine family. From a structure 
activity viewpoint, it is clear that minor structural differences can have a marked effect on the 
biological activity of the pyridoacridine class of compounds. It is worth noting that amphimedine (4), 
despite its low abundance relative to the toxic pyridoacridines also present in the extract, displayed 
observable activity in fairly crude fractions. This suggests that modest fractionation schemes that can Mar. Drugs 2010, 8       
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be carried out in parallel with many extracts at low cost can be sufficient to allow detection of 
compounds causing interesting phenotypes, even in the presence of cytotoxic compounds. 
Figure 3.  Additional developmental defects resulting from amphimedine treatment.   
In situ hybridization was performed on control (A, C, E, G, I, K, M, O, Q) and treated  
(B, D, F, H, J, L, N, P, R) embryos harvested at 24 h (ntl, hnf6, myoD, dlx2, otx2, fgf8, 
zash1a, id6) or 48 h (crx) post treatment. Scale bars, 50 µM. not, notochord; sc, spinal 
cord; som, somites; pa, pharyngeal arches; fb, forebrain; mb, midbrain; mhb, mid/hindbrain 
boundary; hb, hindbrain; pfb, pectoral fin bud; e, eye. 
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3. Experimental Section 
3.1. General Experimental Procedures 
UV spectra were acquired in spectroscopy grade MeOH using a Hewlett-Packard 8452A diode array 
spectrophotometer. IR spectra were recorded on a JASCO FT/IR-420 spectrometer. NMR data for 
compounds  1–3  were acquired using a Varian INOVA 500 (
1H 500 MHz, 
13C 125 MHz) NMR 
spectrometer with a 3mm Nalorac MDBG probe or Varian INOVA 600 (
1H 600 MHz, 
13C 150 MHz) 
NMR spectrometer with a 5 mm Cold Probe for compound 2 referenced to residual solvent  
(δH 2.49, δC 39.51 for DMSO-d6; δH 3.30, δC 49.15 for CD3OD; and δH 1.94, δC 118.69 for CD3CN). 
High-resolution ESIMS analyses were performed on a Micromass Q-tof micro. Initial purification was 
performed on HP20SS resin. HPLC was performed on an Agilent 1100 system using Luna  
Phenyl-Hexyl  (Phenomenex, Inc.) (250  ×  10 mm, 5 µm;  250  ×  4.6 mm, 5 µm) and Luna C18 
(Phenomenex, Inc.) (250 × 4.6 mm, 5 µm) columns. 
3.2. Biological Material 
In order to obtain sufficient quantity of metabolites for biological testing, a large-scale collection of 
the source sponge was conducted. This sponge is identical to the material, Xestospongia  cf. 
carbonaria, from which we previously reported the isolation of neoamphimedine [19]. This sponge is 
readily distinguished by its unique growth form, dark green staining pigmentation, and habitat. There 
has been confusion over its taxonomic placement, and it appears in the literature under several genus 
names including Amphimedon, Axinyssa, Neopetrosia, Pellina, and Xestospongia. Further investigation 
is needed to determine the correct taxonomic assignment of this sponge. 
3.3. Extraction and Isolation 
The Xestospongia cf. carbonaria specimen (1.206 kg) was extracted with 100% MeOH (3 × 1.8 L) 
to yield 54.26 g of crude extract. The crude extract was adsorbed on a 450 × 75 mm column packed 
with 80 g HP20SS resin that was sequentially eluted with 2 L each of water (FW), 25% (F1),   
50% (F2), 75% (F3), and 100% (F4) IPA in water followed by 100% MeOH (F5). Fraction F1 (1.06 g) 
was partitioned between CHCl3 (3 × 200 mL) and 70% MeOH (aq; 200 mL). The dried aqueous 
MeOH phase was further fractionated by HPLC phenyl-hexyl employing MeOH/aqueous TFA (0.1%) 
gradients resulting  in the isolation of compound 1  (1.0 mg), 2  (0.8 mg), 3  (3.0 mg), and 
deoxyamphimedine (6, 10.1 mg). Purification of the HP20SS F2 fraction yielded amphimedine (4,  Mar. Drugs 2010, 8       
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1.2 mg) and neoamphimedine (5, 5.1 mg). Compounds 4–6  were identified by  comparison to   
known standards. 
1-Hydroxy-deoxyamphimedine  (1):  Trifluoroacetate salt; red-orange amorphous solid;   
UV (MeOH) λmax (log ε) 204 (4.51), 246 (4.35), 286 (sh, 4.16), 392 (3.92) nm; IR (film) νmax 3382, 
2925, 2854, 1687, 1598, 1507, 1206, 1136, 801, 723 cm
-1; 
1 H NMR and 
13C NMR data, see Table 1; 
HRESIMS m/z 314.0945 [M]
+ (calcd for C19H12N3O2, 314.0930). 
3-Hydroxy-deoxyamphimedine  (2):  Trifluoroacetate salt; orange-yellow amorphous solid; UV 
(MeOH) λmax (log ε) 206 (4.95), 244 (4.94), 394 (3.34), 488 (3.24) nm; IR (film) νmax 3421, 2925, 
1685, 1505, 1443, 1210, 1139, 844, 803, 724 cm
-1; 
1  H NMR and 
13C NMR data, see Table 1; 
HRESIMS m/z 314.0938 [M]
+ (calcd for C19H12N3O2, 314.0930). 
Debromopetrosamine  (3): Trifluoroacetate salt; purple-blue amorphous solid; UV (MeOH) λmax 
(log ε) 216 (4.49), 282 (4.74), 374 (3.38), 592 (3.15) nm; IR (film) νmax 3063, 1682, 1648, 1588, 1498, 
1206, 1129, 801, 722 cm
-1; 
1 H NMR and 
13C NMR data, see Table 1; HRESIMS m/z 344.1415 [M]
+  
(calcd for C21H18N3O2, 344.1399). 
3.4. Zebrafish Screen 
Danio rerio (zebrafish) were maintained as previously described [27]. Fertilized embryos were 
collected following natural spawnings in 2X PTU (1X E3 medium, 30.4 mg/L phenylthiouera). 
Embryos were periodically checked for death and developmental delay. At seven  hours  
post-fertilization (hpf), embryos were arrayed in 96-well plates at 1 embryo/well. Pure compounds 
were then added to the desired concentration, with dimethyl sulfoxide (DMSO) as vehicle control. 
DMSO was kept at 0.5% of the total assay volume. Embryos were grown at 28.5 °C and examined 
visually with a dissecting microscope at 1, 2, 3 and 6 days post treatment. Early toxicity was noted by 
examining the embryos at 1, 5, and 17 hours post treatment. Embryos were photographed live. All 
experiments were repeated at least twice, in duplicate. 
In situ hybridizations were performed as previously described using digoxigenin-labeled riboprobes 
for crx  (cone rod homeobox),  dlx2  (distal-less homeobox  protein 2),  fgf8  (fibroblast growth 
factor 8), hnf6 (hepatocyte nuclear factor-6), id6 (inhibitor of DNA-binding/differentiation 6), 
myoD  (myogenic differentiation1),  ntl  (no tail),  otx2  (orthodentical homeobox protein 2)  and  
zash1a (zebrafish achaete/scute homologue 1a) [28]. Embryos were photographed with an Olympus 
SZX12 digital camera. 
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